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Genetic variation at the MYH9 locus is linked to the high
incidence of focal segmental glomerulosclerosis (FSGS) and
non-diabetic end-stage renal disease among African Americans.
To further define risk alleles with FSGS we performed a
genome-wide association analysis using more than one
million single-nucleotide polymorphisms in 56 African-American
and 61 European-American patients with biopsy-confirmed
FSGS. Results were compared to 1641 European Americans
and 1800 African Americans as unselected controls. While no
association was observed in the cohort of European
Americans, the case–control comparison of African Americans
found variants within a 60kb region of chromosome 22
containing part of the APOL1 and MYH9 genes associated
with increased risk of FSGS. This region spans different
linkage disequilibrium blocks, and variants associating with
disease within this region are in linkage disequilibrium
with variants which have shown signals of natural selection.
APOL1 is a strong candidate for a gene that has undergone
recent natural selection and is known to be involved in the
infection by Trypanosoma brucei, a parasite common in Africa
that has recently adapted to infect human hosts. Further
studies will be required to establish which variants are
causally related to kidney disease, what mutations caused
the selective sweep, and to ultimately determine if these
are the same.
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Focal and segmental glomerulosclerosis (FSGS) is a common
pattern of renal injury. This injury pattern is observed in
patients with idiopathic proteinuria, in association with
various forms of primary renal injury, and can be the pattern
of injury observed in highly penetrant inherited forms of
kidney disease. In the past decade, several loci have been
identified in families affected with FSGS using genetic
linkage analysis. Rare deleterious mutations that segregate
with disease have subsequently been identified from
fine mapping the regions identified by these methods in
NPHS2 (at chr1q25–q31),1 ACTN4 (chr19q13),2 TRPC6
(chr11q21–q22),3,4 and PLCE1 (chr10q23).5 NPHS2 muta-
tions are responsible for a non-trivial fraction of pediatric
FSGS and steroid-resistant nephrotics syndrome, but only a
small percentage of adult-onset disease. Coding-region
variations in the other genes mentioned explain the disease
in very few patients with ‘sporadic’ non-familial FSGS.6–12
A significant disparity in the frequency of FSGS between
African Americans and people of European ancestry is well
described.13 African Americans have approximately four
times the risk of FSGS compared with European Americans.
Recent work14,15 studying the genetics of this disparity by
admixture analysis identified a region of chromosome
22 with excess African ancestry in the genome of African-
American patients. These studies have suggested that a
specific haplotype near the MYH9 gene and located within
this region of increased African ancestry, denoted E-1,
associates with FSGS and other non-diabetic kidney diseases,
including human immunodeficiency-associated nephropathy
and hypertensive renal disease, in African Americans.
Although the genetic penetrance and absolute risk of FSGS
to an individual with the E-1 haplotype is relatively low, the
population attributable risk can be considered to be high.
We performed a genome-wide association analysis of
sporadic biopsy-confirmed FSGS subjects with either African
or European ancestry using a dense set of more than one
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million single-nucleotide polymorphisms (SNPs) included
on the Illumina (San Diego, CA, USA) 1M-Duo array. We
reasoned that common genetic factors may be high in
magnitude of effect in cases, thus allowing us to use relatively
small numbers of cases, matched for ethnicity, to a large
control data set. We used samples from the Illumina iControl
(http://www.illumina.com/science/icontroldb.ilmn) database
genotyped on the Illumina 550Kv3 array matched for
ancestry to the cases.
Our analysis shows that the association between the
chromosome 22 locus and FSGS risk is because of a genetic
variant or variants that are likely to have arisen relatively
recently in the African population. This region spans the
APOL1 and MYH9 genes. Recent literature suggests recent
selective pressure in Africa on the APOL1 locus, because of
Trypanosoma brucei rhodesiense, a subclade of T. brucei that
recently adapted to be able to affect human hosts.16 This
selective pressure would explain why this long haplotype has
attained high frequency in people of African descent, and
makes APOL1 a good candidate for explaining the fourfold
increase in FSGS in African Americans. This also raises
the distinct possibility that a disease-influencing alteration in
MYH9 was brought to high frequency because of linkage
with APOL1.
RESULTS
We used DNA extracted from whole blood samples from
individuals with biopsy-confirmed FSGS and no family
history of FSGS for these studies. These samples were
collected as part of our ongoing studies on the genetic basis
of FSGS in accordance with a protocol approved by the
institutional review board at the Brigham and Women’s
Hospital. We performed genome-wide SNP genotyping using
Illumina microarrays. We genotyped DNA from 56 African
Americans and 61 individuals of European descent with
FSGS. We excluded individuals with a strong family history
of FSGS from this analysis. We used data from 1827 African-
American and 1641 European-American individuals as a
control data set.
European Americans
Genome-wide association was performed on 61 European
FSGS samples by comparing their genotype frequencies with
data from 1641 unselected European-American controls.
We initially performed a principal component analysis for
the 61 cases and 1641 controls. We excluded 110 of these
controls whom we found to have a significant amount of
non-European ancestry. In this method, the genotype of each
sample is thought as a vector with one component for each
SNP. The set of all these vectors is then projected to a lower
dimensional space that best preserves the distances among
the vectors.
The two-dimensional principal component analysis plot
of the remaining samples is shown in Figure 1. Dimensions
above the second did not show any further significant
population structure. We performed an independent
association analysis of each SNP concordant between the
Illumina 1M-Duo and 550Kv3 chips by comparing allele
frequency. We used the Fisher’s exact test using Plink
software17 because of the small number of cases used.
Because of the small sample size, we were powered only to
find variants with strong effect.
We detected no significant associations for European-
American cases, using a Bonferroni genome-wide significance
level of Po5 108, which is a widely used and highly
conservative method used to address the problem of multiple
tests in genome-wide association studies. We performed
follow-up genotyping with a number of the SNPs that were
shown to associate with a lower significance P-value o105
in a larger cohort of 229 European-American cases. We were
unable to replicate any of these associations, leading us to
conclude that there are no common variants with large effect
with respect to susceptibility to FSGS. Because no common
variants were found, this confirmed our belief that stratifica-
tion did not create false-positive associations.
African Americans
Genome-wide association testing was performed among 56
African-American FSGS samples and 1827 African-American
controls.
In the African-American samples, we performed a
preliminary principal component analysis of cases and
controls. We excluded 68 controls from further study as the
analysis showed that these individuals had ancestry that
was neither European nor African. The two-dimensional
principal component analysis of the remaining samples is
visualized in Figure 2. Dimensions above the first one did not
show significant population structure. The first dimension,
shown horizontally, represents the amount of European
ancestry. We computed the amount of European ancestry in
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Figure 1 |Principal component analysis (PCA) of European-
American samples. The 61 cases are shown and the 1531
controls are plotted. The main axis of variation indicates genetic
variation between southern and northern Europeans,32 whereas
the cluster on the left represents individuals of Ashkenazi
ancestry.
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our cases to verify that this was not statistically different
among cases and controls.
In Figure 3, a histogram shows the amount of European
ancestry in the African-American cases, computed using the
hidden Markov model described in the Materials and
Methods. The average European ancestry of the cases was
18% (with s.d. of 12%), whereas the average European
ancestry of the controls was 17% (with s.d. of 9%) similar to
the percentage previously reported.18 Again, because of the
small sample size and the fact that no significant difference in
European ancestry was found among cases and controls,
stratification was not considered an issue.
We first determined which SNPs were genotyped on both
the 1M-Duo and the 550Kv3 Illumina chip platforms. Given
the small number of cases (n¼ 56) genotyped using the
1M-Duo chip, we performed an independent association
analysis of each matching SNP between the two chips using
Fisher’s exact test on allele frequencies, using Plink soft-
ware.17 Only one locus showed genome-wide significant
associations. In Table 1 we show the nine SNPs with a P-value
o107 that associated with the disease. These were all
located in and around the MYH9 locus on chromosome 22.
We could not directly measure the association for haplotype
E-1 defined in Kopp et al.,14 which is mostly identified by the
risk alleles for SNPs rs4821481 and rs3752462, as this last
variant was genotyped only in cases. However, Hapmap data
for the African Yoruba population show that SNP rs8141971
is a good proxy for rs3752462, with very high linkage
disequilibrium (LD; r240.9). Therefore, we also measured
the frequencies and associations for haplotype E-1p, which is
defined by the risk alleles for SNP rs4821481 and rs8141971,
and for haplotype T-1, defined by the risk alleles for SNP
rs2239785 and SNP rs136187. We picked these two SNPs as
they were found to be the best predictor for the disease
among all possible pairs of SNPs from Table 2. Interestingly,
these SNPs are in significant (LD) in African Yoruba samples
from Hapmap (D0 ¼ 0.43, r2¼ 0.07) whereas almost in
complete linkage equilibrium in European samples from
Hapmap (D0 ¼ 0.12, r2¼ 0.002). We performed the haplotype
analysis using Plink.
To determine which SNPs associate with the disease,
rather than associate with ancestry, we performed a
controlled analysis of a 1000-kb region on chromosome 22
from position 34,500 kb to position 35,500 kb (NCBI36.3
coordinates). Using the Hidden Markov Model described in
the Materials and Methods, we identified 54 cases and 1141
controls whose two chromosomes are both of African
ancestry in this same 1000 kb region. As we expected, most
of the SNPs that previously associated with FSGS were shown
to be artifacts of ancestry alone. Importantly, we found many
previously unidentified SNPs that associated strongly with
FSGS over many LD blocks. These blocks include genes
APOL1, APOL2, APOL4, as well as MYH9. By investigating
the patterns of LD in this 1000 kb region from the African
Yoruba Hapmap participants,19 we conclude that the disease-
causing variant is likely contained in a long 60 kb region
(NCBI36.3 chromosome 22 position 34,982,110–35,044,581
defined by SNPs rs7284919 and rs2239784 that contains part
of APOL1 as well as part of MYH9) that spans several
different LD blocks. In Table 2 we show results for those
SNPs that associated after ancestry correction with a P-value
of Do105, and for haplotype E-1p and T-1.
We also performed an analysis controlling for haplotypes
E-1p. To avoid uncertainty in the phase, we restricted this
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Figure 3 |Histogram of the amount of European ancestry
measured by identifying recombination loci between African
chromosomes and European chromosomes in the 56
African-American cases analyzed. The X axis shows the
fractional amount of European ancestry. The Y axis indicates
the sample count.
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Figure 2 |Principal component analysis of African-American
samples. The 56 cases are shown in red and the 1759 controls are
plotted in blue. The horizontal axis of variation differentiates
African ancestry, on the right, with European ancestry, on the left.
Different positions on the first axis represent differing amounts of
ancestry across the samples, as it is expected to be observed for
recently admixed populations.
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analysis to samples homozygous for the risk alleles defining
E-1p. In Table 3 we report association results of Fisher’s exact
test for ten SNPs that associated with a P-value of o103
within samples of this subset. It is clear that controlling for E-
1p falls far from explaining the large disparity observed for
variants within APOL1.
In Figure 4 the genes APOL1 and MYH9 are represented,
together with the location of the recombination hotspots that
were predicted from Hapmap data. The main recombination
hotspot between APOL1 and MYH9 has been estimated to
have an intensity of 0.2 cm from Hapmap data. Stated
differently, this means that variants on different sides of
Table 1 | Fisher’s exact test association results for single-nucleotide polymorphisms (SNPs) that associated with a P-value
o107, haplotype E-1p defined by risk alleles for rs4821481 and rs8141971, and haplotype T-1 defined by risk alleles for
rs2239785 and rs136187 in the African-American cohort
Chromo-
some
SNP
identifier
Physical
position
(NCBI36.3)
Risk
allele
Frequency of risk allele in
African-American
cases (n=56)
Frequency of risk allele
in African-American
controls (n=1759)
Frequency of risk
allele in European
controls (n=1531)
Non-risk
allele P-value
22 rs4821469 34946391 C 0.8 0.52 0.08 T 9.31 1010
22 rs713753 34988480 C 0.96 0.78 0.42 T 6.82 108
22 rs2239785 34991276 G 0.94 0.64 0.21 A 4.59 1013
22 rs4821475 34999041 T 0.79 0.54 0.24 C 3.51 108
22 rs4821481 35025888 C 0.89 0.63 0.05 T 1.28 109
22 rs2157256 35037607 A 0.91 0.66 0.35 G 1.36 109
22 rs4820230 35039485 G 0.91 0.66 0.35 A 2.17 109
22 rs8141971 35041308 A 0.95 0.74 0.35 G 4.70 108
22 rs16996672 35055916 T 0.56 0.27 0 C 2.56 1010
E-1p 0.88 0.6 0.04 1.21 109
T-1 0.65 0.31 0.14 4.10 1014
Table 2 | Fisher’s exact test association results for single-nucleotide polymorphisms (SNPs) that associated with a P-value
o105, haplotype E-1p defined by risk alleles for rs4821481 and rs8141971, and haplotype T-1 defined by risk alleles for
rs2239785 and rs136187 in the cohort of African Americans who were detected as having two African chromosomes in the
22q12.3 region
Chromo-
some
SNP
identifier
Physical
position
(NCBI36.3)
Risk
allele
Frequency of risk allele
in corrected African-
American cases (n=54)
Frequency of risk allele in
corrected African-American
controls (n=1141)
Frequency of risk
allele in European
controls (n=1531)
Non-risk
allele P-value
22 rs7364143 34932129 T 0.64 0.42 0.26 G 7.49 106
22 rs2239785 34991276 G 0.95 0.74 0.21 A 1.90 108
22 rs4821475 34999041 T 0.81 0.59 0.24 C 1.60 106
22 rs136187 35002222 C 0.69 0.46 0.61 A 1.47 106
22 rs2157256 35037607 A 0.91 0.73 0.35 G 9.52 106
22 rs4820230 35039485 G 0.91 0.73 0.35 A 9.51 106
22 rs16996672 35055916 T 0.58 0.33 0 C 1.99 107
E-1p 0.9 0.71 0.04 3.35 105
T-1 0.67 0.36 0.14 7.64 1011
Table 3 | Fisher’s exact test association results for single-nucleotide polymorphisms (SNPs) that associated with a P-value
o103 and haplotype T-1 defined by risk alleles for rs2239785 and rs136187 in the cohort of African Americans who were
detected as being homozygous for the E-1p haplotype defined by risk alleles for rs4821481 and rs8141971
Chromo-
some
SNP
identifier
Physical
position
(NCBI 36.3)
Risk
allele
Frequency of risk allele
in corrected African-
American cases (n=43)
Frequency of risk allele in
corrected African-American
controls (n=617)
Frequency of risk
allele in European
controls (n=1531)
Non-risk
allele P-value
22 rs4821469 34946391 C 0.83 0.65 0.08 T 8.51 104
22 rs136148 34982877 T 1 0.9 0.67 C 2.08 104
22 rs713753 34988480 C 0.98 0.86 0.42 T 7.45 104
22 rs2239785 34991276 G 0.97 0.77 0.21 A 1.30 106
22 rs4821475 34999041 T 0.86 0.64 0.24 C 1.75 105
22 rs136187 35002222 C 0.72 0.5 0.61 A 7.96 105
22 rs16996672 35055916 T 0.65 0.44 0 C 1.23 104
22 rs11089788 35081047 A 0.52 0.34 0.5 C 6.19 104
22 rs136211 35088493 A 0.71 0.52 0.32 G 4.89 104
22 rs16996704 35094734 A 0.77 0.56 0.88 G 1.77 104
T-1 0.71 0.42 0.14 1.04 107
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the hotspot are farther away at a genetic distance equivalent
to a physical distance of approximately 200 kb, whereas the
30 ends of the two genes are o20 kb away from each other.
It is clear from this picture that strong associations are still
detected even after correction for ancestry from different
LD blocks. Supplementary Figures 1 and 2 show patterns of
LD for the African Yoruba population from Hapmap and the
European population from Hapmap.
DISCUSSION
In this paper, we describe the results of a dense genome-
wide scan in two small groups of individuals with FSGS:
one African-American and the other European-American.
We were unable to identify any reproducible associations
between FSGS and common genetic variants in European
cases compared with unselected controls, which suggests that
there are no common variants in the European population
of large effect in the susceptibility to disease (because our
sample size was small, we cannot exclude the existence of
genetic variants of small effect). We replicated the signal
originating from the MYH9 locus that has been previously
observed.14,15 This signal did not replicate in European
samples, although the statistical power to detect a true
association was limited by the relatively small number of
cases available for study. We did not find any other signal
outside of the MYH9 locus. Given the strong association at
this locus for African Americans, this association explains
most of FSGS in this cohort, and therefore we were extremely
underpowered to identify any additional and independent
association.
Although these results are preliminary and we have not
identified a clear causal variant that accounts for the
increased FSGS risk in African Americans, they still suggest
that given the stronger association that we observed for
haplotype T-1 compared with haplotype E-1p, a close proxy
for haplotype E-1 studied in Kopp et al.,14 the causal variant
has a larger penetrance than previously thought. Although
haplotype E-1 has a frequency close to 60% in African
Americans, haplotype T-1 has a frequency close to 30%.
This frequency likely reflects more faithfully the frequency of
the causal variant than haplotype E-1, which shows that the
prevalence of this variant is lower than recently thought and
that, once identified, it may in fact have a clinical effect and
significant clinical utility.
Patterns of LD in African Yoruba (YRI) and Europeans
(CEU) from Hapmap show that there are some variants at
this locus that are in strong LD in Africans and that this
LD spans both sides of a number of putative recombination
hotspots. According to Hapmap, MYH9 SNPs rs11912763,
rs16996648, rs5756152, rs16996672, and rs16996677
(NCBI36.3 chromosome 22 position 35,014,668,
35,022,698, 35,042,418, 35,055,916, and 35,057,229, respec-
tively) show strong LD with variants in APOL1 (see Supple-
mentary Figures 1 and 2), have high minor allele frequency,
and they are nearly nonexistent in the European populations.
At the same time, signals of natural selection in the region
have previously been identified in African Yoruba samples
and never in European samples within a region containing
genes APOL3, APOL4, APOL2, APOL1, and MYH9
(NCBI36.3 coordinates 34,800–35,100 kb) in publicly avail-
able databases using the long-range haplotype test,19 the
integrated haplotype score,20,21 the ratio of most frequent
haplotype homozygosity,22 and the composite of multiple
signals.23 In this last study, the strongest signal of selection
was found for variant rs9622363 (NCBI36.3 position
34,986,501, genome-wide composite of multiple signal
14.987, P¼ 1.3 105, untyped in our study) and according
to Hapmap this variant in African Yoruba is in strong LD
with rs7364143 (D0 ¼ 0.7, r2¼ 0.18), rs2239785 (D0 ¼ 1.0,
r2¼ 0.8), rs136187 (D0 ¼ 0.7, r2¼ 0.14), and rs1699672
(D0 ¼ 0.6, r2¼ 0.07), which is four out of seven of the
variants in Table 2. It is therefore possible that the disease-
causing variant rose to higher frequency in Africans because
of a selective sweep that took place near or at the MYH9 locus
in the African population, and which was recent enough to
leave extensive patterns of LD. The Illumina chips that we
used for genotyping, despite being the densest commercially
available at the time of this study, do not have sufficient
numbers of SNPs that are highly polymorphic in the African
population to allow us to be more precise at the present time.
This is likely because of an ascertainment bias in the
way SNPs have been discovered with, until recently,
a reliance on non-African samples.
Recently, the 1000 Genomes project (http://www.
1000genomes.org/) released sequence and variation data
from the DNS samples used in Hapmap data. These data,
accessible through the Integretive Genomics Viewer (http://
www.broadinstitute.org/igv/), show the existence of many
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Figure 4 |Position of APOL1 and the 30 end of MYH9. Base pair position on chromosome 22 according to NCBI36.3 is shown on the
top, whereas below imputed Hapmap recombination rates identifying hotspots are shown together with a diagram of the exons contained
in APOL1 and MYH9. The recombination hotspot between APOL1 and MYH9 has been estimated to have an intensity of 0.2 cm from
Hapmap data. Figure obtained with NCBI’s Sequence Viewer (http://www.ncbi.nlm.nih.gov/projects/sviewer/).
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variants at the APOL1–MYH9 locus that are observed at high
frequency in Africans but are rare or nonexistent in
Europeans and Asians and have not been analyzed in
Hapmap. Recent studies24,25 based on variants genotyped in
Hapmap failed in defining a clear candidate for causal asso-
ciation. If it is in fact true that one single variant can explain
the association between this locus and FSGS, then it is likely
that it is one of the variants that are highly polymorphic
exclusively among Africans, but rare or nonexistent in non-
Africans, which would explain the lack of replication of
association of this locus in other large studies in different
populations.26 The small level of associations observed in
Europeans by others14 could also be explained by low levels of
African ancestry in the cases considered or even by the fact
that Southern European populations have a 1–3% level of
African ancestry because of migrations that took place 50–70
generations ago (Nick Patterson, private communication).
Interestingly, it has been recently shown that mutations in
the C-terminal region of APOL1 interfere with the interac-
tion of the serum resistance-associated (SRA) protein with
APOL1, which is the mechanism by which T. brucei
rhodesiense evades the trypanolytic activity of APOL1 that
normally confers resistance to the parasite.27,28 This suggests
a potential explanation for a selective sweep that would have
taken place in those regions in Africa where the T. brucei
rhodesiense has evolved and human infection has become
widespread. If this is indeed the case, such a sweep is pro-
bably no more than a few thousands years old, as it is
believed that the SRA protein evolved in T. brucei rhodesiense
when humans had become more numerous.29 It is possible
that the association of the variants caught up in this selective
sweep with increased risk of kidney disease is incidental,
although there may be more subtle mechanisms awaiting
elucidation.
MATERIALS AND METHODS
Cases and controls
We genotyped 61 European-American (36 males and 25 females,
average age at diagnosis 36.0±17.5) and 56 African-American
(26 males and 30 females, average age at diagnosis 22.5±14.5)
patients with idiopathic biopsy-proven FSGS and no family history
of FSGS using the Illumina 1M-Duo platform. Patients were
recruited in accordance with protocols approved by the relevant
human research committees from medical centers in the eastern
United States, mainly from New York City. We used 1641 unselected
European-American samples and 1827 unselected African-American
samples genotyped with the Illumina 550Kv3 platform from the
iControldb database (http://www.illumina.com/science/icontroldb.
ilmn). In brief, we downloaded all genotyping data available from
genotyping studies that used the Illumina 550Kv3 array using
‘European American’ (n¼ 1641) or ‘African American’ (n¼ 1827) as
the selection criteria. These two data sets were then converted to
Plink format using scripts that we developed (Ross Lazarus,
unpublished data). We matched cases and control data sets based
on their ethnicity. After correction for ancestry, 110 European-
American controls and 68 African-American controls were excluded
on the basis of excessive ancestry that was neither European nor
African. This left 1531 European-American controls and 1759
African-American controls for our study. Cases were tested for
cryptic relatedness looking for long segments identical by descent,
showing that all cases were unrelated.
Genotyping
Genotyping was performed at the Broad Institute of Harvard and
Massachusetts Institute of Technology. In the cases, out of the
1,199,187 variants analyzed using the Illumina 1M-Duo chip,
47 variants were discarded because they showed discordant
clustering among different Illumina chips (private communication,
Illumina Technical Support, 11 August 2009), 56,590 variants were
excluded because 410% of genotypes were missing in African
Americans, and 58,524 were excluded for similar reasons in
European Americans. In controls, out of 549,837 variants in African
Americans, 7,298 variants were excluded because of missing 410%
of genotypes, and out of 561,255 variants in European Americans
19,051 were excluded for the same reason. Almost all of the variants
in the Illumina 550Kv3 chip are also included in the Illumina
1M-Duo chip, and hence there was not an additional loss of coverage
when comparing results for the two platforms. Strand issues were not
a concern, because C/G or A/T SNPs are not genotyped in the
Illumina 550Kv3 platform—these polymorphisms can give rise to
spurious case–control comparisons when other genotyping platforms
are used, a frequent cause of problems if the data describing which
strand is used to code the SNPs are incorrect or unavailable.
Admixture determination
To identify which regions of the genome in African-American cases
and controls had African or European origin, we used a hidden
Markov model with three hidden states corresponding to the
number of chromosomes of European ancestry at a given locus.
Given a polymorphic locus t in the genome, we indicate with pE(t)
the frequency of the reference allele in the European population,
p0E(t) the frequency of the reference allele in the Illumina European
cohort, with pA(t) the frequency of reference allele in the African
population, with p0B(t) the frequency of the reference allele in the
Illumina African-American cohort, and m¼ 21% the expected
European ancestry in the African-American samples. We approxi-
mated the ancestral frequencies of the two populations using the
Illumina controls cohort in the following way:
pEðtÞ  p0EðtÞ
pAðtÞ  p
0
BðtÞ  mp0EðtÞ
1m
This method of estimating the two allele frequencies is conceptually
much simpler than the one described in Patterson et al.,30 which uses
a Markov chain Monte Carlo approach to estimate the frequencies
from both the cases and controls. Differences between these
frequencies is not an important concern given the overwhelmingly
large number of controls genotyped and given that we already know
the average frequency of European ancestry in African Americans.
Following the notation in Durbin et al.,31 we set the emission
probabilities ejk(t) for j,k¼ 0.2, where j indicates the number of
chromosomes of European ancestry at a given locus and k indicates
the number of non reference alleles observed at that locus, as
e ¼
p2A 2pAð1 pAÞ ð1 pAÞ2
pApE pAð1 pEÞ þ ð1 pAÞpE ð1 pAÞ ð1 pEÞ
p2E 2pEð1 pEÞ ð1 pEÞ2
0
@
1
A
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where for clarity we have dropped the variable t indicating the locus,
and we set the transmission probabilities aij for i,j¼ 0.2, where i,j
indicate the number of chromosomes of European ancestry at a given
locus and the next locus, as
a ¼
1 e e2 e e2
e 1 2e e
e2 e 1 e e2
0
@
1
A
where eB240 is chosen small enough to avoid short false positives.
For the admixture determination of the region in between 34,500
and 35,500 kb (NCBI36.3 coordinates), all 242 SNPs common to the
two platforms for cases and controls were used.
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